Motesanib and advanced NSCLC: Experiences and expectations

Expert Opinion on Investigational Drugs

Volumn 20, Issue 6, 2011, Pages 859-869

  Raghav, Kanwal Pratap Singh ^a,b   Blumenschein, George R ^a,c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Unit 0421   (United States)

^c Faculty Center (FC92060)   (United States)

Author keywords

angiogenesis; motesanib; MTKI; NSCLC; VEGF

Indexed keywords

BEVACIZUMAB; MOTESANIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; STEM CELL FACTOR; VASCULOTROPIN RECEPTOR 1;

ANGIOGENESIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MECHANISM; HUMAN; LUNG NON SMALL CELL CANCER; METASTASIS; OVERALL SURVIVAL;

ADMINISTRATION, ORAL; ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; CARCINOMA, NON-SMALL-CELL LUNG; DRUG DELIVERY SYSTEMS; HUMANS; INDOLES; LUNG NEOPLASMS; NIACINAMIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79955827262     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.2011.579103     Document Type: Article

References (46)

1. Jemal A, Siegel R, Xu J, et al. Cancer Statistics, 2010. CA Cancer J Clin 2010;60(5):277-300
2. Wahbah M, Boroumand N, Castro C, et al. Changing trends in the distribution of the histologic types of lung cancer: a review of 4,439 cases. Ann Diagn Pathol 2007;11:89-96 (Pubitemid 46350914)
3. Spiro SG, Rudd RM, Souhami RL, et al. Big Lung Trial participants. Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life. Thorax 2004;59:828-36 (Pubitemid 39389621)
4. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-32 (Pubitemid 41058344)
5. Schiller JH, Harrington D, Belani CP, et al. Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-8 (Pubitemid 34438899)
6. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57
7. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11:121-8
8. Scagliotti G, Hanna N, Fossella F, et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist 2009;14:253-63
9. Algire GH. Vascular reactions of normal and malignant tissues in vivo. VII. Observations on vascular reactions in destruction of tumor homografts. J Natl Cancer Inst 1954;15:483-91
10. Folkman J, Merler E, Abernathy C, Williams G. Isolation of a tumor factor responsible for angiogenesis. J Exp Med 1971;133:275-88
11. Folkman J. Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg 1972;175:409-16
12. Senger DR, Van de Water L, Brown LF, et al. Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev 1993;12:303-24 (Pubitemid 23293287)
13. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992;359:843-5
14. Connolly DT, Heuvelman DM, Nelson R, et al. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest 1989;84:1470-8 (Pubitemid 19272234)
15. Karpanen T, Egeblad M, Karkkainen MJ, et al. Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res 2001;61:1786-90 (Pubitemid 32691984)
16. Brown LF, Berse B, Jackman RW, et al. Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am J Pathol 1993;143:1255-62 (Pubitemid 24057094)
17. Brown LF, Berse B, Jackman RW, et al. Expression of vascular permeability factor (vascular endothelial growth factor)and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res 1993;53:4727-35 (Pubitemid 23304407)
18. Ohta Y, Endo Y, Tanaka M, et al. Significance of vascular endothelial growth factor messenger RNA expression in primary lung cancer. Clin Cancer Res 1996;2:1411-16 (Pubitemid 26299442)
19. Rini BI, Halabi S, Rosenberg JE, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008;26:5422-8
20. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized Phase III study. J Clin Oncol 2008;26:2013-19.
21. Erratum in: J Clin Oncol 2009;27:653
22. J Clin Oncol 2008;26:3110
23. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50. (Pubitemid 44917502)
24. Erratum in: N Engl J Med 2007;356:318
25. Goss GD, Arnold A, Shepherd FA, et al. Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study. J Clin Oncol 2010;28:49-55
26. Glade BJ, Cooney EM, Kandel JJ, Yamashiro DJ. Vascular remodeling and clinical resistance to antiangiogenic cancer therapy. Drug Resist Updat 2004;7:289-300 (Pubitemid 39469101)
27. Faivre S, Djelloul S, Raymond E. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors. Semin Oncol 2006;33:407-20 (Pubitemid 44142738)
28. Herbst RS, O'Neill VJ, Fehrenbacher L, et al. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol 2007;25:4743-50 (Pubitemid 350086476)
29. Herbst RS, Sun Y, Eberhardt WE, et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol 2010;11:619-26
30. Socinski MA, Novello S, Brahmer JR, et al. Multicenter, Phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 2008;26:650-6 (Pubitemid 351264362)
31. Scagliotti G, Novello S, von Pawel J, et al. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol 2010;28:1835-42
32. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-24 (Pubitemid 46089672)
33. George S, Blay JY, Casali PG, et al. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer 2009;45:1959-68
34. Polverino A, Coxon A, Starnes C, et al. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res 2006;66:8715-21 (Pubitemid 44449188)
35. Rosen LS, Kurzrock R, Mulay M, et al. Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. J Clin Oncol 2007;25:2369-76 (Pubitemid 46999207)
36. Li C, Kuchimanchi M, Hickman D, et al. In vitro metabolism of the novel, highly selective oral angiogenesis inhibitor motesanib diphosphate in preclinical species and in humans. Drug Metab Dispos 2009;37:1378-94
37. Blumenschein GR Jr, Reckamp K, Stephenson GJ, et al. Phase lb study of motesanib, an oral angiogenesis inhibitor, in combination with carboplatin/ paclitaxel and/or panitumumab for the treatment of advanced non-small cell lung cancer. Clin Cancer Res 2010;16:279-90
38. Blumenschein GRJr, Kabbinavar F, Menon H, et al. A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer. Ann Oncol. 2011. [Epub ahead of print]
39. Amgen. A Phase 3, multicenter, randomized, placebo-controlled, double-blind trial of AMG 706 in combination with paclitaxel and carboplatin for advanced non-small cell lung cancer. ClinicalTrials.gov NCT00460317. Available from: http:// clinical trials. gov/ct2 /show/ NCT00460317?term=motesanib+and +lung+cancer&rank=3 [Last accessed 13 April 2011]
40. Dingemans AM, de Langen AJ, van den Boogaart V, et al. First-line erlotinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer: a phase II study including molecular imaging. Ann Oncol 2011;22:559-66
41. Blumenschein GR Jr, Gatzemeier U, Fossella F, et al. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer. J Clin Oncol 2009;27:4274-80
42. Sawaki A, Yamada Y, Komatsu Y, et al. Phase II study of motesanib in Japanese patients with advanced gastrointestinal stromal tumors with prior exposure to imatinib mesylate. Cancer Chemother Pharmacol 2010;65:961-7
43. Sherman SI, Wirth LJ, Droz JP, et al. Motesanib Thyroid Cancer Study Group. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 2008;359:31-42 (Pubitemid 351931094)
44. Kruser TJ, Wheeler DL, Armstrong EA, et al. Augmentation of radiation response by motesanib, a multikinase inhibitor that targets vascular endothelial growth factor receptors. Clin Cancer Res 2010;16:3639-47
45. Bass MB, Sherman SI, Schlumberger MJ, et al. Biomarkers as predictors of response to treatment with motesanib in patients with progressive advanced thyroid cancer. J Clin Endocrinol Metab 2010;95:5018-27
46. Ellis LM, Hicklin DJ. Pathways mediating resistance to vascular endothelial growth factor-targeted therapy. Clin Cancer Res 2008;14:6371-5